TY - JOUR
T1 - Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma
T2 - A Prospective Study Within the Nationwide Netherlands Cancer Registry
AU - Wester, Ruth
AU - Dinmohamed, Avinash G
AU - van der Holt, Bronno
AU - Zweegman, Sonja
AU - Minnema, Monique
AU - Croockewit, Sandra
AU - Levin, Mark-David
AU - Libourel, Eduard
AU - de Waal, Esther
AU - Sonneveld, Pieter
AU - Cornelissen, Jan
AU - Blijlevens, Nicole
AU - Broijl, Annemiek
N1 - Funding Information:
Support by Netherlands Comprehensive Cancer Organisation, The Haemato Oncology Foundation for Adults in the Netherlands (HOVON), and Dutch Cancer Foundation.
Funding Information:
RW received honoraria from Sanofi and Janssen. SZ received advisory from Takeda, Janssen, BMS-Celgene, Sanofi, Oncopeptides, and Amgen; and research funding from Takeda and Janssen. MM received consultancy from Janssen, Cilag, Gilead, Alnylam; and speaker of BMS, Hospitality BMS. EdW received honoraria from Celgene en Janssen. PS received research support from Amgen, BMS/Celgene, Janssen, Karyopharm, and SkylineDx; and advisory/honoraria from Amgen, BMS/Celgene, Carsgen, GSK, Janssen, Karyopharm, Seagen, and SkylineDx. AB received honoraria/advisory from BMS, Sanofi, Janssen, and Amgen. All the other authors have no conflicts of interest to disclose.
Publisher Copyright:
© 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
PY - 2022/2
Y1 - 2022/2
N2 - Patients with relapsed and/or refractory multiple myeloma (RRMM) generally have limited treatment options and a poor prognosis. Previous trials demonstrated that pomalidomide combined with low-dose dexamethasone (Pd) is effective in these patients with significant responses and improved progression-free survival (PFS). Pd has been approved in RRMM patients who received ≥2 prior lines of therapy. Here, we present the results of a population-based study of patients with RRMM treated with Pd in The Netherlands from time of pomalidomide approval. Using the nationwide Netherlands Cancer Registry, data from all nontrial patients with RRMM treated with Pd were collected. Data were analyzed of response, PFS, and overall survival (OS). A total of 237 patients were included in this analysis. Previous treatment consisted of a proteasome inhibitor in 227 patients (96%) and/or an immune-modulating agent in 235 patients (99%). One hundred forty patients (59%) were refractory to an immune-modulating agent in their last line of therapy. Median time from diagnosis to treatment with Pd was 4.9 years (interquartile range, 2.7-7.9), and the median number of prior treatments was 4 (interquartile range, 3-5). Median PFS and OS for all patients were 3.6 months (95% confidence interval [CI], 3.1-3.8) and 7.7 months (95% CI, 5.7-9.7), respectively. For patients achieving ≥PR, median PFS and OS were 10.6 months (95% CI, 8.3-12.9) and 16.3 months (95% CI, 13.6-23.2), respectively. This nationwide, population-based registry study confirms data shown in pivotal clinical trials on Pd. PFS in this analysis is comparable to PFS observed in those clinical trials.
AB - Patients with relapsed and/or refractory multiple myeloma (RRMM) generally have limited treatment options and a poor prognosis. Previous trials demonstrated that pomalidomide combined with low-dose dexamethasone (Pd) is effective in these patients with significant responses and improved progression-free survival (PFS). Pd has been approved in RRMM patients who received ≥2 prior lines of therapy. Here, we present the results of a population-based study of patients with RRMM treated with Pd in The Netherlands from time of pomalidomide approval. Using the nationwide Netherlands Cancer Registry, data from all nontrial patients with RRMM treated with Pd were collected. Data were analyzed of response, PFS, and overall survival (OS). A total of 237 patients were included in this analysis. Previous treatment consisted of a proteasome inhibitor in 227 patients (96%) and/or an immune-modulating agent in 235 patients (99%). One hundred forty patients (59%) were refractory to an immune-modulating agent in their last line of therapy. Median time from diagnosis to treatment with Pd was 4.9 years (interquartile range, 2.7-7.9), and the median number of prior treatments was 4 (interquartile range, 3-5). Median PFS and OS for all patients were 3.6 months (95% confidence interval [CI], 3.1-3.8) and 7.7 months (95% CI, 5.7-9.7), respectively. For patients achieving ≥PR, median PFS and OS were 10.6 months (95% CI, 8.3-12.9) and 16.3 months (95% CI, 13.6-23.2), respectively. This nationwide, population-based registry study confirms data shown in pivotal clinical trials on Pd. PFS in this analysis is comparable to PFS observed in those clinical trials.
UR - https://www.scopus.com/pages/publications/85124221047
U2 - 10.1097/HS9.0000000000000683
DO - 10.1097/HS9.0000000000000683
M3 - Article
C2 - 35106452
SN - 2572-9241
VL - 6
SP - 1
EP - 6
JO - HemaSphere
JF - HemaSphere
IS - 2
M1 - e683
ER -